表紙
市場調査レポート

ニコチン中毒症:パイプライン製品の分析

Nicotine Addiction - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 245978
出版日 ページ情報 英文 60 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
ニコチン中毒症:パイプライン製品の分析 Nicotine Addiction - Pipeline Review, H1 2016
出版日: 2016年03月16日 ページ情報: 英文 60 Pages
概要

ニコチン中毒症は、ニコチンへの薬物依存によって引き起こされるタバコ製品への依存症です。年齢、抑うつ傾向、統合失調症、PTSD、アルコール依存などの要因によって発病し、摂取中止の際には手の震え、発汗、神経過敏、心拍数の上昇などといった離脱症状がでる場合もあります。ニコチン置換療法などにより治療を行います。

当レポートでは、ニコチン中毒症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

ニコチン中毒症の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

ニコチン中毒症:企業で開発中の治療薬

ニコチン中毒症:大学/機関で研究中の治療薬

ニコチン中毒症:パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品

ニコチン中毒症:企業で開発中の製品

ニコチン中毒症:大学/機関で研究中の製品

ニコチン中毒症の治療薬開発に従事している企業

  • Addex Therapeutics Ltd
  • Astraea Therapeutics, LLC
  • Cerecor Inc.
  • Embera NeuroTherapeutics, Inc.
  • Hager Biosciences, LLC
  • Heptares Therapeutics Limited
  • Omeros Corporation
  • RTI International

ニコチン中毒症:治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

ニコチン中毒症:最近のパイプライン動向

ニコチン中毒症:休止中のプロジェクト

ニコチン中毒症:開発が中止された製品

ニコチン中毒症:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7741IDB

Summary

Global Markets Direct's, 'Nicotine Addiction - Pipeline Review, H1 2016', provides an overview of the Nicotine Addiction pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Nicotine Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nicotine Addiction and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Nicotine Addiction
  • The report reviews pipeline therapeutics for Nicotine Addiction by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Nicotine Addiction therapeutics and enlists all their major and minor projects
  • The report assesses Nicotine Addiction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Nicotine Addiction

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Nicotine Addiction
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Nicotine Addiction pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • List of Tables
  • List of Figures
  • Introduction
  • Global Markets Direct Report Coverage
  • Nicotine Addiction Overview
  • Therapeutics Development
  • Pipeline Products for Nicotine Addiction - Overview
  • Pipeline Products for Nicotine Addiction - Comparative Analysis
  • Nicotine Addiction - Therapeutics under Development by Companies
  • Nicotine Addiction - Therapeutics under Investigation by Universities/Institutes
  • Nicotine Addiction - Pipeline Products Glance
  • Clinical Stage Products
  • Early Stage Products
  • Nicotine Addiction - Products under Development by Companies
  • Nicotine Addiction - Products under Investigation by Universities/Institutes
  • Nicotine Addiction - Companies Involved in Therapeutics Development
  • Addex Therapeutics Ltd
  • Astraea Therapeutics, LLC
  • Cerecor Inc.
  • Embera NeuroTherapeutics, Inc.
  • Hager Biosciences, LLC
  • Heptares Therapeutics Limited
  • Omeros Corporation
  • RTI International
  • Nicotine Addiction - Therapeutics Assessment
  • Assessment by Monotherapy Products
  • Assessment by Combination Products
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Drug Profiles
  • (metyrapone + oxazepam) - Drug Profile
  • Product Description
  • Mechanism of Action
  • R&D Progress
  • ADX-71441 - Drug Profile
  • Product Description
  • Mechanism of Action
  • R&D Progress
  • AT-1001 - Drug Profile
  • Product Description
  • Mechanism of Action
  • R&D Progress
  • CERC-501 - Drug Profile
  • Product Description
  • Mechanism of Action
  • R&D Progress
  • Drugs to Inhibit FAAH for CNS Disorders - Drug Profile
  • Product Description
  • Mechanism of Action
  • R&D Progress
  • EORA-101 - Drug Profile
  • Product Description
  • Mechanism of Action
  • R&D Progress
  • OMS-405 - Drug Profile
  • Product Description
  • Mechanism of Action
  • R&D Progress
  • OMS-527 - Drug Profile
  • Product Description
  • Mechanism of Action
  • R&D Progress
  • Small Molecule to Antagonize Alpha-4 Beta-2 Nicotinic Acetylcholine Receptor for CNS Disorders - Drug Profile
  • Product Description
  • Mechanism of Action
  • R&D Progress
  • Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile
  • Product Description
  • Mechanism of Action
  • R&D Progress
  • Small Molecules to Antagonize CRF-R1 and OREXIN-1 for Nicotine Addiction - Drug Profile
  • Product Description
  • Mechanism of Action
  • R&D Progress
  • Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile
  • Product Description
  • Mechanism of Action
  • R&D Progress
  • Small Molecules to Inhibit Dopamine, Serotonin, Norepinephrine Transporters for Central Nervous System Disorders - Drug Profile
  • Product Description
  • Mechanism of Action
  • R&D Progress
  • Vaccine for Nicotine Addiction - Drug Profile
  • Product Description
  • Mechanism of Action
  • R&D Progress
  • Vaccine for Nicotine Addiction - Drug Profile
  • Product Description
  • Mechanism of Action
  • R&D Progress
  • Nicotine Addiction - Recent Pipeline Updates
  • Nicotine Addiction - Dormant Projects
  • Nicotine Addiction - Discontinued Products
  • Nicotine Addiction - Product Development Milestones
  • Featured News & Press Releases
  • Dec 11, 2015: Publication Reports Human Brain Penetration and Target Engagement of Cerecor's Oral Kappa Opioid Receptor Antagonist, CERC-501
  • Jul 10, 2014: Addex ADX71441 Positive Results in Preclinical Model of Nicotine Addiction
  • Mar 19, 2013: Omeros Elucidates Mechanism Of PDE7 Inhibitors In Addiction
  • May 05, 2011: Omeros Announces Expansion Of Potential Indications For PDE7 Inhibitors
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Nicotine Addiction, H1 2016
  • Number of Products under Development for Nicotine Addiction - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Nicotine Addiction - Pipeline by Addex Therapeutics Ltd, H1 2016
  • Nicotine Addiction - Pipeline by Astraea Therapeutics, LLC, H1 2016
  • Nicotine Addiction - Pipeline by Cerecor Inc., H1 2016
  • Nicotine Addiction - Pipeline by Embera NeuroTherapeutics, Inc., H1 2016
  • Nicotine Addiction - Pipeline by Hager Biosciences, LLC, H1 2016
  • Nicotine Addiction - Pipeline by Heptares Therapeutics Limited, H1 2016
  • Nicotine Addiction - Pipeline by Omeros Corporation, H1 2016
  • Nicotine Addiction - Pipeline by RTI International, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Nicotine Addiction Therapeutics - Recent Pipeline Updates, H1 2016
  • Nicotine Addiction - Dormant Projects, H1 2016
  • Nicotine Addiction - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Nicotine Addiction, H1 2016
  • Number of Products under Development for Nicotine Addiction - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top